Aims and objectives

The ESCMID Study Group for Non-Traditional Antibacterial Therapy (ESGNTA) brings together professionals from various expertise dedicated to advancing the use of bacteriophages and other new non-traditional therapeutic approaches to treat infectious diseases. Our mission includes: 

  • Developing microbiological guidelines and supporting the clinical use of phages and phage-derived products, via clinical trials and compassionate use
  • Identifying bacterial pathogens and infectious disease indications where non-traditional antibacterials, including bacteriophage therapies, may lead to cure or improved clinical outcomes
  • Increasing knowledge and fostering research on phage-derived enzymes, especially lysins, to identify the optimal carriers and applications in clinical settings, such as gels and nanoparticles
  • Creating a network and promoting the establishment of academic phage therapy centres across European countries, based on the models developed in Belgium, France, Israel, Australia, and the USA

Activities and resources

ESGNTA Newsletter, Spring 2024, April 2024 


ESGNTA Newsletter, Spring 2024, March 2024 


ESGNTA Newsletter, Winter 2023, February 2023 


ESGNTA Newsletter, Spring 2023, April 2023 


ESGNTA Newsletter, Summer 2023, August 2023


ESGNTA Newsletter, Autumn 2023, November 2023

Phages and phage-borne enzymes as new antibacterial agents. 

McCallin S, Drulis-Kawa Z, Ferry T, Pirnay JP, Nir-Paz R. Clin Microbiol Infect. 2023;20:S1198-743X(23)00528-1.

Go to publication

Personalized Phage Therapy: Basic Principles of monitoring and treatment: Supplement 5 1 Nov 2023 

Nir-Paz R, Iredell J, Suh G, Fabijan AP. Clinical Infectious Diseases, Vol 77, Issue Supplement 5, 1 November 2023.

Go to publication

Global Clinical Phage Rounds 8 

Lessons learned (so far) from treating patients with phage therapy for antibiotic-resistant bacterial infections

Global Clinical Phage Rounds 7 

Inhaled Bacteriophage Therapy for Multi-Drug Resistant Achromobacter

Global Clinical Phage Rounds 6 

The French Experience

Global Clinical Phage Rounds 5 

Case Discussion – How long is enough: duration of phage therapy for NTM infections in three Australian patients?

Global Clinical Phage Rounds 4 

Belgian Published cases

Global Clinical Phage Rounds 3 

Case Discussion – Urgent cases on Mycobacterium

Global Clinical Phage Rounds 2 

Case Discussion – Renal transplant and recurrent UTIs

ESGNTA as part of the VOM2023 conference 

7 July 2023, The George Eliava Institute of Bacteriophages, Tbilisi, Georgia Congress

Go to course

Personalized phage therapy: from the lab to the patient 

Technical workshop

Go to course

Executive Committee

  Ran Nir-Paz

Ran Nir-Paz

Hadassah-Hebrew University Medical Center. Clinical Microbiology and infectious Diseases
Jerusalem, Israel
  Tristan Ferry

Tristan Ferry

Education Officer
Hospices Civils de Lyon. Infectious Diseases
Lyon, France
  Jean-Paul Pirnay

Jean-Paul Pirnay

Science Officer
Queen Astrid Military Hospital. LabMCT
Brussels, Belgium
  Gina Suh

Gina Suh

Mayo Clinic
Rochester, United States
  Zuzanna Drulis-Kawa

Zuzanna Drulis-Kawa

University of Wroclaw. Department of Pathogen Biology and Immunology


If you have questions or comments for our study group, we warmly invite you to contact us!

Contact form